10x Genomics Raises 2026 Outlook to $620 Million as Q2 Sales Fall 12.6%

2 articles · Updated · Yahoo Finance UK · Aug 10

$151 million in Q2 revenue topped analyst estimates of $146.5 million, even as 10x Genomics' sales fell 12.6% from a year earlier and its GAAP loss narrowed to $0.14 per share.
Lower instrument sales drove the decline because customers held back on Xenium and Visium purchases ahead of the new Atera spatial platform, which management said is drawing stronger-than-expected orders.
$620 million is the new full-year revenue midpoint, up from $612.5 million and about 1% above Wall Street estimates, with most Atera placements and related revenue expected in the fourth quarter.
Manufacturing capacity—not demand—is limiting Atera shipments this year, while Chromium consumables growth and AI-driven demand across academic and biopharma customers underpin management's longer-term growth case.